Business
Director's Dealing
Director's Dealing.
About this update from Gunsynd Plc
[{"type":"text","content":"\n \nRNS Number : 3836G Syntopix Group plc 11 May 2011 \n \n\n \n \n\n\n\n\nPress Release\n\n\n11 May 2011\n\n\n\n\n \nSyntopix Group plc\n \n(\"Syntopix\" or \"the Company\")\n \n \nDirector's Dealing\n \n \nSyntopix Group plc (AIM:SYN), the speciality pharmaceutical research and development company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, has today been notified that, on 10 May 2011, Tom Bannatyne, Chairman of the Company, acquired 140,000 ordinary shares of 10p each in the Company, at a price of 48p per share. Following this purchase Mr Bannatyne has a beneficial interest in 646,467 ordinary shares representing approximately 6.03 per cent. of the Company's issued share capital.\n \n- Ends -\n \nFor further information, please contact:\n \n\n\n\n\nSyntopix Group plc\n\n\n\n\n\n\n\nDr Stephen Jones, Chief Executive Officer\n\n\n+44 (0)845 125 9204\n\n\n\n\nTom Bannatyne, Chairman\n\n\nwww.syntopix.com\n\n\n\n\n \n\n\n\n\nZeus Capital Ltd\n\n\n\n\n\n\n\nAlex Clarkson\n\n\nTel: +44(0)161 831 1512 \n\n\n\n\nTom Rowley\n\n\nwww.zeuscapital.co.uk\n\n\n\n\n \n\n\n\n\nXCAP Securities Plc\n\n\n\n\n\n\n\nKaren Kelly/Jon Belliss/Parimal Kumar\n\n\nTel: +44(0) 207 101 7070 \n\n\n\n\n\n\n\nwww.xcapgroup.co.uk\n\n\n\n\n \n \nMedia enquiries:\n\n\n\n\nAbchurch Communications\n\n\n\n\n\n\n\nSarah Hollins/Adam Michael\n\n\nTel: +44 (0) 20 7398 7708\n\n\n\n\[email protected]\n\n\nwww.abchurch-group.com\n\n\n\n\n \n \nNotes to editors\nAbout Syntopix Group plc\nSyntopix is a specialised research and development business, focusing on topical antimicrobial innovations for products in consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds. \n \nSyntopix has a robust pipeline, with a growing library of over 3,000 compounds screened and characterised for antimicrobial activity. Its strategy is to seek to reduce the risks and costs of drug discovery and development by discovering novel uses for known compounds and combinations of compounds, which have established safety profiles. \n \nFr...